Purdue Pharma

Purdue Pharma
source
Name	Purdue Pharma
Foundation	0 1892
Founders	John Purdue Gray, George Frederick Bingham
Location	Stamford, Connecticut, United States
Key people	Mortimer Sackler, Raymond Sackler, Richard Sackler
Industry	Pharmaceutical industry
Products	OxyContin, MS Contin, Dilaudid
Fate	Bankruptcy and dissolution

Purdue Pharma was a privately held American pharmaceutical company founded in 1892. It is infamously known for its aggressive marketing of the prescription opioid painkiller OxyContin, a drug that became central to the opioid epidemic in the United States. The company and its owners, the Sackler family, faced thousands of lawsuits for their role in fueling the public health crisis, ultimately leading the company to file for Chapter 11 bankruptcy in 2019. Its operations and assets were largely dissolved as part of a contentious settlement to fund opioid abatement programs.

History

The company was originally established in New York City as the Purdue Frederick Company by John Purdue Gray and George Frederick Bingham. For much of its early history, it operated as a modest seller of patent medicines like Gray's Glycerine Tonic. A transformative shift occurred in 1952 when physicians Mortimer Sackler and Raymond Sackler purchased the firm. Under their leadership, Purdue began developing more potent pain management drugs, including MS Contin, a sustained-release formulation of morphine launched in the 1980s. This success in controlled-release technology paved the way for the company's most significant and notorious product. The company was later renamed and relocated its headquarters to Stamford, Connecticut.

OxyContin and the opioid crisis

In 1996, the company launched OxyContin, its timed-release version of oxycodone. The drug was aggressively marketed to physicians with claims, later found to be misleading, that its controlled-release formulation posed a lower risk of addiction and drug abuse. The company's marketing tactics, directed by executives like Richard Sackler, included funding pain management seminars and influencing organizations like the American Pain Society. These efforts contributed to a massive increase in prescriptions for chronic non-cancer pain. The widespread availability and misuse of OxyContin, often crushed to defeat its time-release mechanism, became a primary driver of the escalating opioid epidemic in the United States, leading to increased rates of overdose and a surge in heroin and fentanyl use.

Legal issues and bankruptcy

Facing mounting public scrutiny and litigation, the company and three executives pleaded guilty in 2007 to federal charges of misbranding OxyContin as less addictive. They paid over $600 million in fines in a settlement with the U.S. Department of Justice. However, lawsuits proliferated, filed by dozens of states, Native American tribes, local governments, and individuals. The litigation alleged the company engaged in deceptive marketing that fueled the public health crisis. In 2019, facing an estimated 3,000 lawsuits, the company filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Southern District of New York. This initiated a complex and years-long bankruptcy proceeding to negotiate a global settlement.

Corporate structure and ownership

The company was privately owned by descendants of its purchasers, the Sackler family, who served on its board of directors and held key executive roles. In the years following the OxyContin launch, billions of dollars in profits were distributed to family members. As legal pressure intensified, the family employed complex financial strategies, including moving funds through Swiss bank accounts and other international entities. A separate entity, Mundipharma, was established to market opioids internationally. The family's holding company, Sackler Trust, also came under intense scrutiny, leading several major cultural institutions, including the Metropolitan Museum of Art and the American Museum of Natural History, to refuse future donations from the Sacklers.

Impact and legacy

The company's dissolution and the associated legal settlements are intended to provide billions of dollars to fund opioid abatement programs across communities devastated by the epidemic. The Sackler family, while not granted legal immunity from all future claims, secured broad protection from civil lawsuits through the bankruptcy deal, a provision that faced significant opposition from several state attorneys general and the U.S. Supreme Court. The saga has profoundly impacted the pharmaceutical industry, leading to tighter regulations on opioid prescribing and greater scrutiny of drug marketing practices. It has also sparked a wider cultural reckoning over corporate accountability and the role of private philanthropy derived from controversial wealth, permanently tarnishing the once-prominent Sackler name. Category:Pharmaceutical companies of the United States Category:Opioid epidemic in the United States Category:Companies established in 1892 Category:Companies that filed for Chapter 11 bankruptcy in 2019